Lupin Reports the US FDA’s Acceptance of sNDA for Solosec (secnidazole) to Treat Bacterial Vaginosis and Trichomoniasis
- The US FDA has approved the sNDA to expand the use of Solosec (secnidazole) for the treatment of bacterial vaginosis in female patients and the treatment of trichomoniasis in patients aged ≥12yrs.
- Additionally, the approval helps to approval expands the indication for Solosec to treat adolescents and builds upon a commitment to support women’s health
- Solosec (2g oral granules) is the first single-dose oral prescription approved therapy & is indicated to treat both bacterial vaginosis (BV) and trichomoniasis. The therapy is designed to be easy to take & a single-dose therapy with a complete course of treatment
Ref: PR Newswire | Image: Lupin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.